Overview

A Phase 2 Clinical Study of ABSK061 and ABSK043

Status:
RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Phase:
PHASE2
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd